Medtronic PLC $MDT Stock Position Lessened by Robinson Value Management Ltd.

Robinson Value Management Ltd. reduced its position in shares of Medtronic PLC (NYSE:MDT) by 12.3% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 45,208 shares of the medical technology company’s stock after selling 6,317 shares during the period. Medtronic comprises about 2.2% of Robinson Value Management Ltd.’s investment portfolio, making the stock its 13th biggest position. Robinson Value Management Ltd.’s holdings in Medtronic were worth $3,901,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in MDT. WCM Investment Management LLC bought a new stake in Medtronic during the first quarter worth about $965,922,000. First Eagle Investment Management LLC increased its holdings in shares of Medtronic by 37.2% during the second quarter. First Eagle Investment Management LLC now owns 13,783,983 shares of the medical technology company’s stock worth $1,078,321,000 after buying an additional 3,739,288 shares in the last quarter. Cullen Capital Management LLC bought a new position in shares of Medtronic in the second quarter valued at approximately $202,764,000. State Street Corp raised its stake in shares of Medtronic by 2.7% in the second quarter. State Street Corp now owns 63,399,315 shares of the medical technology company’s stock valued at $5,005,320,000 after acquiring an additional 1,658,301 shares during the last quarter. Finally, Amundi raised its stake in shares of Medtronic by 36.3% in the first quarter. Amundi now owns 6,070,236 shares of the medical technology company’s stock valued at $525,986,000 after acquiring an additional 1,616,739 shares during the last quarter. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic received the CE mark for its five-device Vitalis pacemaker portfolio. The devices use conduction system pacing to stimulate the heart’s natural electrical pathways, giving Medtronic a potential product and competitive-positioning opportunity in European markets. Medtronic’s next-gen pacemaker portfolio secures CE mark
• Positive Sentiment: The company appointed Michael Marinaro as president with an expanded role and completed the MiniMed spinoff. The changes could sharpen Medtronic’s strategic focus and allow management to concentrate more closely on its core medical-device businesses. Medtronic appoints new president and completes MiniMed spinoff
• Neutral Sentiment: Industry research projects continued growth in U.S. wireless cardiac monitoring, supported by reimbursement expansion, telehealth adoption and AI-enabled wearables. The trend is favorable for Medtronic’s cardiac portfolio, but the report does not announce new company-specific revenue or contracts. U.S. Wireless Cardiac Monitoring Systems Market Size, Share, and Forecast
• Neutral Sentiment: Recent trading commentary noted that MDT had underperformed during the prior session despite broader market gains. This reflects short-term market positioning rather than a new fundamental development. Medtronic Stock Dips While Market Gains: Key Facts
• Negative Sentiment: Medtronic insiders disclosed sizable stock sales, including an executive’s preplanned sale of 10,420 shares valued at roughly $1 million and a CEO sale reported at approximately $4.75 million. Because the transactions were planned, they may not signal deteriorating business prospects, but their size can weigh on sentiment. Medtronic Insider Sold Shares Worth $1,000,320
• Negative Sentiment: ETFs recorded approximately $94.9 million in net selling of MDT on October 16, indicating some passive or quantitative-fund pressure, though the impact may be temporary. Medtronic Sees $94.9 Million in Net ETF Selling

Insiders Place Their Bets

In other Medtronic news, EVP Harry Kiil sold 1,483 shares of the stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $93.65, for a total transaction of $138,882.95. Following the completion of the transaction, the executive vice president owned 42,186 shares in the company, valued at approximately $3,950,718.90. This represents a 3.40% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Michael Marinaro sold 10,420 shares of Medtronic stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $96.00, for a total value of $1,000,320.00. Following the completion of the sale, the executive vice president directly owned 105,916 shares in the company, valued at $10,167,936. This represents a 8.96% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 61,903 shares of company stock worth $5,889,203. Corporate insiders own 0.27% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently commented on MDT. TD Cowen reissued a “buy” rating and issued a $110.00 target price on shares of Medtronic in a report on Wednesday, September 30th. Royal Bank Of Canada reaffirmed an “outperform” rating and set a $118.00 price target on shares of Medtronic in a report on Wednesday, September 2nd. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $92.00 price objective on shares of Medtronic in a research report on Thursday, September 3rd. Stifel Nicolaus boosted their price objective on Medtronic from $80.00 to $95.00 and gave the stock a “hold” rating in a research note on Wednesday, September 2nd. Finally, Piper Sandler restated a “neutral” rating on shares of Medtronic in a report on Wednesday, October 14th. Eighteen research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $102.88.

Medtronic Stock Performance

Medtronic stock opened at $94.56 on Wednesday. Medtronic PLC has a 1 year low of $73.31 and a 1 year high of $106.33. The company’s 50-day moving average is $91.18 and its two-hundred day moving average is $85.11. The company has a current ratio of 2.07, a quick ratio of 1.54 and a debt-to-equity ratio of 0.50. The company has a market cap of $120.96 billion, a PE ratio of 23.29, a PEG ratio of 2.17 and a beta of 0.55.

Medtronic (NYSE:MDT) last posted its quarterly earnings results on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, topping analysts’ consensus estimates of $1.39 by $0.06. The business had revenue of $9.76 billion during the quarter, compared to the consensus estimate of $9.55 billion. Medtronic had a net margin of 13.93% and a return on equity of 14.78%. Medtronic’s revenue for the quarter was up 13.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.26 earnings per share. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Equities analysts anticipate that Medtronic PLC will post 5.98 earnings per share for the current year.

Medtronic Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, October 16th. Investors of record on Friday, September 25th were paid a $0.72 dividend. The ex-dividend date of this dividend was Friday, September 25th. This represents a $2.88 dividend on an annualized basis and a yield of 3.0%. Medtronic’s dividend payout ratio is presently 70.94%.

Medtronic Profile

Medtronic plc (NYSE: MDT) is a global medical technology company that develops, manufactures and distributes devices and therapies used to diagnose, treat and manage a broad range of medical conditions. Its products support healthcare providers in areas including cardiac and vascular care, diabetes, neuroscience, surgical procedures and patient monitoring.

The company’s offerings include pacemakers, implantable defibrillators, heart valves and other structural heart products; insulin pumps and continuous glucose monitoring technologies; spinal and neurosurgical systems; deep-brain and spinal cord stimulation devices; surgical instruments and robotic-assisted technologies; and respiratory and patient-monitoring equipment.